FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 209 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 31-Year-Old Woman Diagnosed with Breast Cancer Just 11 Days Before Her... June 21, 2021 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... October 19, 2021 Load more HOT NEWS Cancer Research UK report highlights stark cancer inequalities across Scotland ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows The Cancer Moonshot: A Midpoint Progress Update
